Reference health
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features
49/49 checkable references clean · checked 2026-07-24
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 49 checked references that resolve
resolves10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
resolves10.1158/0008-5472.CAN-10-0190
Integrated Profiling Reveals a Global Correlation between Epigenetic and Genetic Alterations in Mesothelioma
resolves10.1158/1078-0432.CCR-13-2429
Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition
resolves10.1073/pnas.1612074113
High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma
resolves10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
resolves10.1158/2159-8290.CD-18-0804
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
resolves10.1038/s41467-019-09307-6
Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
resolves10.1038/sj.onc.1208744
Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth
resolves10.1371/journal.pone.0105919
MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
resolves10.1016/j.lungcan.2014.08.004
Identification of actionable mutations in malignant pleural mesothelioma
resolves10.1016/j.ejcts.2007.09.045
PTEN expression is a strong predictor of survival in mesothelioma patients☆
resolves10.1016/j.lungcan.2016.03.001
Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)
resolves10.1200/JCO.2006.09.7634
Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study
resolves10.1038/onc.2013.280
Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma
resolves10.1002/jcp.26830
Inactivation of
<i>Tp53</i>
and
<i>Pten</i>
drives rapid development of pleural and peritoneal malignant mesotheliomas
resolves10.1073/pnas.0707761105
The p110β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ
resolves10.1016/S1074-7613(01)00134-0
T Cell-Specific Loss of Pten Leads to Defects in Central and Peripheral Tolerance
resolves10.1038/ng747
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer
resolves10.1126/scisignal.2004088
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
resolves10.1155/2013/765748
National Mesothelioma Virtual Bank: A Platform for Collaborative Research and Mesothelioma Biobanking Resource to Support Translational Research
resolves10.1038/nature07091
Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
resolves10.1158/1078-0432.CCR-16-1971
Co-occurring Mutations of Tumor Suppressor Genes,
<i>LATS2</i>
and
<i>NF2</i>
, in Malignant Pleural Mesothelioma
resolves10.1164/rccm.201404-0658OC
Fibroblast Growth Factor Receptor Inhibition Is Active against Mesothelioma and Synergizes with Radio- and Chemotherapy
resolves10.1158/1535-7163.MCT-15-0846
Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition
<i>In Vitro</i>
resolves10.3390/ijms19051297
In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM)
resolves10.3390/ijms19082191
Mesotheliomas in Genetically Engineered Mice Unravel Mechanism of Mesothelial Carcinogenesis
resolves10.1097/JTO.0b013e3182333df5
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
resolves10.1186/s12881-018-0651-4
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications
resolves10.1080/2162402X.2015.1009285
The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers
resolves10.1371/journal.pone.0106742
Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
resolves10.1016/j.jtho.2017.02.013
The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma
resolves10.18632/oncotarget.13017
MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival
resolves10.1158/2159-8290.CD-12-0003
Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent
resolves10.1158/1078-0432.CCR-12-3815
PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines
resolves10.1158/1078-0432.CCR-15-2225
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
resolves10.1158/1078-0432.CCR-14-1814
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
resolves10.1158/2159-8290.CD-16-0795
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic
<i>BRAF</i>
-Mutant Colorectal Cancer
resolves10.1158/1535-7163.MCT-15-0496
Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/
<i>BRAF</i>
-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K
<b>β</b>
-Selective Inhibitor
The 1 reference without a DOI — listed, not checked
no DOI — not checkedSubunit structure and enzymic activity of pertussis toxin
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-24 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1158/0008-5472.can-19-1633"><img src="https://citestamp.com/citestamped/10.1158/0008-5472.can-19-1633/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1158/0008-5472.can-19-1633)